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Abstract
Background: Malaria is considered a public health priority in Haiti, with a goal to eliminate by year 2020. Chloroquine is the first-line treatment recommended by the Ministry of Public Health and Population. In order to verify the
suitability of chloroquine for uncomplicated malaria treatment, an in vivo study of susceptibility of Plasmodium falciparum to chloroquine was conducted from January 2013 to March 2015 in six localities in the south of Haiti.
Results: Sixty-one patients who presented with confirmed P. falciparum malaria were included in the study and
followed until day 28 after having taken 25 mg/kg of chloroquine orally over 3 days. The sample included 28 children
under the age of 10, 9 adolescents aged 10–19 years, and 24 adults aged 20 years and over. Among them, 30 were
monitored on day 3 (49%) and 33 on day 28 (59%). Clinical and parasitological monitoring was carried out on day 7 on
28 subjects, on day 14 on 13 subjects and on day 21 on 18 subjects. Residual parasitaemia with presence of trophozoites was found in 7 of 30 subjects on day 3 (23%), and in 6 of 28 subjects on day 7 (21%) who had a temperature less
than 37.5 °C. These patients can be considered as late parasitological failures. All monitoring performed on day 28 was
negative. Gametocytes were found in 3 patients (9%) despite the use of primaquine. The continuing low parasitaemia
on day 3 and 7 in more than one fifth of cases raises the question of the efficacy of chloroquine in southern Haiti.
Conclusions: Results suggest a decrease of chloroquine susceptibility for treatment of P. falciparum malaria cases in
southern Haiti. Consequently, there is a need to strengthen malaria treatment surveillance and to study the effectiveness of chloroquine in Haiti by monitoring patients after treatment.
Keywords: Malaria, Plasmodium falciparum, Chloroquine susceptibility, Haiti
Background
Malaria is considered a public health priority in Haiti [1–
4], even though the transmission rate is low [5]. In Haiti,
infections are believed to be entirely due to Plasmodium
falciparum, and strains are believed to be susceptible
to chloroquine, which is still often used in therapy, and
remains the first-line treatment recommended by the
Ministère de la Santé Publique et de la Population (the
Ministry of Public Health and Population). Surveillance
information of patients treated for malaria in Haiti is very
*Correspondence: raccurt@yahoo.fr
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limited. Recent studies have found P. falciparum isolates
carrying chloroquine resistant genes [6, 7]. Additionally, therapeutic failures of oral chloroquine treatment
have been reported [8]. In order to verify the suitability
of chloroquine for uncomplicated malaria treatment, a
study of in vivo susceptibility of P. falciparum was conducted from January 2013 to March 2015 in three departments in Haiti (Ouest, Sud-Est, Grande Anse).

Methods
Study sites

The study was carried out in six coastal sites in three geographic departments in Haiti (Fig. 1). In these six sites,
patients were recruited from two hospitals: Hôpital
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Fig. 1 Location of sites where subjects were included in the study of chloroquine susceptibility of Plasmodium falciparum in three departments of
the south of Haiti: 1 Petit-Goâve, 2 Corail, 3 Jérémie, 4 Bariadelle, 5 Cayes-Jacmel, 6 Anse-à-Bœuf

Notre-Dame in Petit-Goâve (Ouest Department) and
Hôpital Saint-Antoine in Jérémie (Grande Anse Department); from three community health centres: Cayes Jacmel (Sud-Est Department), Corail and Bariadelle (Grande
Anse Department); and from a village known as a place
of high transmission, remote from any health structure:
Anse-à-Bœuf (Sud-Est Department).
Subjects

Study participation included febrile patients and villagers
with an axillary temperature greater or equal to 37.5 °C at
baseline, and those who had a fever with chills within the
prior 24 h. Inclusion criteria were: P. falciparum monoinfection with a parasitaemia ≥to 1000 asexual forms per
microlitre of blood (evaluation for mono-infection was by
direct microscopy), axillary temperature ≥37.5 °C on the
day of the survey or fever and chills within the prior 24 h,
no signs of severe or complicated malaria, and no antimalarial treatment within the previous 2 weeks. Study

objectives were explained in Haitian Creole and patients
were included after having given their written consent, or
that of a parent or legal guardian for minors.
A rapid diagnostic test (RDT) for P. falciparum and non-P.
falciparum malaria (First R
 esponse®-CareStartTM Malaria
Rapid Test) was performed. Questioning and a clinical
examination looking for signs of malaria were conducted
by the same physician (CPR) among the positive patients
included in the study. For each subject, a capillary blood
sample was taken from the fingertip to make a thick and
thin blood smear. Research, identification and counting of
sexual and asexual forms of P. falciparum were conducted at
1000× magnification. Subjects with less than 1000 asexual
forms per microlitre were excluded from the study. Blood
was collected on Whatman 9
 03® filter paper for genotyping of the parasite strain (results not yet published). Patients
were treated with chloroquine and primaquine according to
dosage recommended by the Ministry of Public Health and
Population, namely, 600 mg of chloroquine and 60 mg of
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primaquine at baseline (D0) and 300 mg of chloroquine on
day 1 and 2 for adults. Children received 10 mg/kg at baseline and 5 mg/kg on day 1 and 2. After administration of
treatment, patients were kept under observation for 30 min
to verify absence of vomiting. In case of vomiting before
30 min passed, a new dose was administered.
Whenever possible, subjects were monitored on day
1, 2, 3, 7, 14, 21 and 28, axillary temperature was monitored, a clinical exam and a thick smear were performed.
The criteria for assessing treatment efficacy were those
defined by the World Health Organization (WHO) [9] to
distinguish adequate clinical and parasitological response
including early failure, late clinical failure, and late parasitological failure.
Laboratory procedures

Thick and thin blood smears were stained using the
Giemsa method and examined under a microscope. The
count of asexual forms of P. falciparum was performed
compared to 200 leukocytes and evaluated by microlitre
of blood while considering a number of 8000 leukocytes
per microlitre of blood.

Results
A total of 71 volunteers presenting with malaria due to P.
falciparum detected by a fever greater than 37.5 °C and/
or a positive RDT confirmed by microscopy of the parasite on the thick smear were enrolled. Only 61 patients
met the inclusion criteria, nine having too low of parasitaemia levels (between 261 and 933 trophozoites/µL),
and one subject was lost after day 1. The 61 retained subjects came from six sites across three geographic regions
(departments) in the south of Haiti (Table 1). 33 subjects
were male and 28 were female. There were 28 children

less than 10 years old, the youngest being 18 months
old; 9 adolescents aged 10–19 years; and 24 adults over
20 years of age (Table 2).
The parasitic density of asexual forms from the 61
monitored subjects varied from 1000 to 277,227 trophozoites/µL (mean: 48,811.5; median: 14,686). The distribution of patients according to age and parasitic density is
given in Table 3. The three patients with the highest levels
of parasitaemia were, respectively, 4 years old (201,538
trophozoites/µL), 5 years old (277,227 trophozoites/µL)
and 7 years old (262,223 trophozoites/µL).
Of the 61 patients included, 30 were monitored on day
3 (49% of the sample). Seven (23.3%) still showed P. falciparum trophozoites in the thick smear, however, in a
smaller quantity than on day 0 and without clinical signs
(temperature <37.5 °C). Six out of 28 still had P. falciparum throphozoites on day 7, but with an axillary temperature <37.5 °C.
By monitoring at a distance, 13 patients were reviewed
at day 14, 18 patients at day 21, and 33 patients at day 28
at the end of the study. Two 2-year-old children showed
persistence of trophozoites in the thick smear until day
21, but with an axillary temperature <37.5 °C. At day 28,
all 33 controlled subjects had a negative thick smear without trophozoites and an axillary temperature <37.5 °C.
Only 3 of them were still gametocyte carriers. During
clinical follow-up, we observed the appearance on day 28
of a level 1 spleen according to the Hackett classification
in a 6-year-old girl and a 72-year-old woman.

Discussion
The results of this study showed a decrease of chloroquine susceptibility for treatment of P. falciparum
malaria cases in southern Haiti. Six patients failed

Table 1 Sites in which subjects were recruited and the number of subjects reviewed at each monitoring
Department

City

Date

Number of subjects enrolled

Number of subjects examined at each monitoring

Day 0

Day 1

Day 2

Day 3

Day 7

Day 14

Day 21

Day 28

Ouest

Petit-Goâve

January 2013

1

NA

NA

1

NA

NA

NA

1

Grande Anse

Corail

January 2013

11

NA

NA

6

NA

NA

NA

6

Grande Anse

Jérémie

February 2013

2

NA

NA

0

NA

NA

NA

1

Sud Est

Cayes Jacmel

March 2013

3

NA

NA

0

NA

NA

NA

2

Grande Anse

Corail

May 2013

2

NA

NA

1

NA

NA

NA

0

Sud Est

Anse-à-Bœuf

January 2014

9

5

5

3

6

7

7

8

Sud Est

Anse-à-Bœuf

February 2014

5

NA

NA

0

4

3

NA

NA

Sud Est

Anse-à-Bœuf

June 2014

4

4

4

4

4

3

3

3

Grande Anse

Bariadelle

February 2015

Totals
NA not applicable

24

21

17

15

14

NA

8

12

61

30

26

30

28

13

18

33

49%

70%

49%

67%

72%

49%

59%
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Table 2 Distribution of subjects by sex and age
Age (years)

Male

Female

≥50

3

3

20–49

9

9

10–19

6

3

1–9

15

13

Total (range 1–75)

33

28

Table 3 Distribution of subjects by age and parasitic density of trophozoites of Plasmodium falciparum per microlitre
Age (years)

Parasitic density of trophozoites/microliters of blood
1000–9999

≥50

20–49

10,000–
49,999

50,000–
149,000

150,000–
300,000

1

3

2

0

9

4

4

2

10–19

2

1

3

2

1–9

13

7

4

4

1–75

25 (41%)

15 (25%)

13 (21%)

8 (13%)

therapy. As chloroquine is inexpensive and commonly
used in Haiti this study has important implications. As
stated by the World Health Organization [10], high parasitaemia is a risk factor for death from malaria. Hyperparasitaemia >250,000 parasites/µL is an additional
criteria for severe malaria in non-immune individuals.
The relation between parasitaemia and prognosis varies
according to the level of malaria transmission. As Haiti
is a low-transmission area [1, 5], it seems probable that
mortality from acute falciparum malaria increases with
parasite densities over 100,000/µL.
Close monitoring of patients during treatment resulted
in a rapid decrease of parasitic density in four out of five
cases. Two 2-year-old children in Anse-à-Bœuf retained
trophozoite parasitaemia on day 14 and 21, but not on
day 28 when only gametocytes were found. Throughout
the entire follow-up period, their axillary temperature
was <37.5 °C. For one patient, parasitaemia decreased
dramatically, going from 3579 trophozoites/µL at baseline to 204/µL at day 14–44/µL at day 21. For the other,
there were 1280 trophozoites at baseline and parasitaemia remained at this same level on day 7, 14, and 21.
These two cases can thus be considered as two late parasitological failures.
Among all patients, the majority or most of the clinical symptoms noted on day 0 disappeared as early as
the day 2 or 3 monitoring, except for the pallor of the
mucous membranes, attesting to the frequent anemia

among children in these villages. The fever decline was
rapid: while nearly half of the patients had an axillary
temperature between 37.5 °C and 40.8 °C at baseline,
only two of 31 patients had, respectively, an axillary
temperature of 37.9 °C and 38.1 °C on day 1, only one
out of 25 on day 2 (37.5 °C), and one out of 30 on day
3 (38.1 °C). Afterward, all patients that were monitored
weekly until day 28 had an axillary temperature of less
than 37.5 °C.
Through questioning and examination, the improvement of clinical status was observed among all patients
during monitoring, indicating that chloroquine remains
effective in Haiti. This study shows that the majority of P.
falciparum isolates remain susceptible, in vivo, to chloroquine in Haiti, as was observed some 30 years ago [11,
12] and until recently in Léogane among 49 patients [13].
However, in a recent study [8], the persistence of parasitaemia among 7 out of 60 asymptomatic patients monitored until day 28 and 42 was observed in the Ouest
department, and interpreted as late parasitological failures. These recent findings are similar to the results
of this study. They likely indicate an onset of decreased
susceptibility of this drug in the treatment of malaria
in Haiti. These in vivo results should be compared with
recent detection of P. falciparum haplotypes carrying
chloroquine resistant genes in Artibonite [6].
Two major difficulties were encountered during this
study. The first was the recruitment of cases that met the
pre-established inclusion criteria. It is currently difficult
to recruit malaria cases in Haiti, except in a few specific
areas such as Anse-à-Bœuf in the Sud-Est department
(N°6 on the map in Fig. 1), and Bariadelle in the Grande
Anse department (N°4). This is why these two sites were
prioritized to conduct this study, despite their distance
from Port-au-Prince, and the difficulty of accessing Anseà-Bœuf. As for the majority of febrile subjects examined
during visits to the health centres, they tested negative
by RDT. This confirms that malaria is not the leading
cause of febrile illness in Haiti. It is, therefore, essential
to achieve precise diagnosis of fevers using the increasingly available rapid tests, to avoid unnecessarily treating
all febrile subjects with anti-malarials.
The second limitation concerns the routine monitoring
of included subjects. Despite their consent to participate
in the study, some subjects were lost and did not return
to their follow-up appointments, which resulted in variation of the days where follow-up monitoring was performed. This loss of patients was experienced less in the
fishing villages of Anse-à-Bœuf and Bariadelle, where it
was easier to find the subjects in their home, in case they
missed monitoring appointments. However, despite this
limitation, the study still indicates the decrease of chloroquine susceptibility by P. falciparum parasites.
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Conclusions
The implications of this study highlight the need to
strengthen surveillance of decreasing in vivo susceptibility of P. falciparum throughout the country in order
to identify the regions affected by these failures in chloroquine treatment. This information is critical in determining appropriate therapeutic and control measures in
Haiti.
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